New Therapies Wet AMD Could Improve Outcomes for Patients | ASRS

Patient perspectives on new treatments for dry AMDПодробнее

ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVOПодробнее

ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMDПодробнее

Treatments for dry AMDПодробнее

The Response of New GA Therapies From Patients, Payers | ASRS 2023Подробнее

Matching Patients to Therapy in Wet AMD: How New Technology May Alleviate Treatment BurdenПодробнее

New and Emerging Treatments for Age-Related Macular Degeneration (AMD)Подробнее

Eye to Eye: AMD TreatmentПодробнее

New treatments for wet AMD, Nigel DaviesПодробнее

Optimizing Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting TherapiesПодробнее

Faricimab - a new treatment for wet AMD and DMOПодробнее

2022 Vitreoretinal and Macular Disease UpdateПодробнее

Changes in vision due to Dry AMDПодробнее

Prof Jonathan Gibson Wet AMD treatmentПодробнее

ASRS 2021: The Pipeline for Wet AMD and GAПодробнее

How can eye clinics improve AMD services?Подробнее

Age-Related Macular Degeneration (AMD) | Current and Emerging TherapiesПодробнее

Retinal Drug Delivery Solutions Panel at Ophthalmology Innovation Summit @ ASRS 2019Подробнее

Macular Degeneration Explained - Diagnosis, Symptoms and Treatment of Dry and Wet AMDПодробнее